AOD-9604 is a synthetic hexadecapeptide analog derived from the C-terminal region of the human growth hormone (hGH) protein, specifically encompassing residues 176–191 with a stabilizing N-terminal tyrosine modification. Originally investigated for its potential to isolate the lipolytic (fat-burning) properties of somatotropin from its growth-promoting and hyperglycemic effects, AOD-9604 has become a significant focal point in preclinical metabolic research. Unlike intact hGH, this fragment does not activate the growth hormone receptor, thereby avoiding the stimulation of insulin-like growth factor 1 (IGF-1) and the associated risks of insulin resistance. Current laboratory investigations focus on its selective modulation of the beta-3 adrenergic receptor pathway, its role in suppressing lipogenesis, and its emerging applications in connective tissue regeneration and cartilage repair. All content is provided strictly for research reference.
Background: The Origin of AOD-9604
The development of AOD-9604 (Advanced Obesity Drug 9604) began as a quest within endocrine research to separate the anabolic (growth-promoting) and metabolic (lipolytic) functions of the human growth hormone (hGH). While native hGH is highly effective at mobilizing adipose tissue, its clinical utility for metabolic disorders was historically limited by significant systemic side effects, most notably the induction of peripheral insulin resistance and the risks associated with chronically elevated IGF-1 levels [1].
In the late 1990s, researchers at Monash University identified that the lipolytic activity of hGH was primarily localized within the C-terminal region of the 191-amino acid protein. Specifically, the fragment encompassing residues 176–191 was found to retain the ability to increase fat oxidation and reduce body weight in obese rodent models without crossing the threshold of the growth hormone receptor [2]. AOD-9604 was engineered as a stabilized version of this fragment, designed to serve as a high-precision tool for studying isolated lipid metabolism in laboratory environments.
Molecular Structure and Modification
AOD-9604 is a synthetic hexadecapeptide with the primary sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe. Structurally, it is often categorized as Tyr-hGH (177-191), reflecting its derivation from the C-terminus of somatotropin.
The defining structural feature of AOD-9604 compared to the raw "fragment 176-191" is the addition of a tyrosine residue at the N-terminus. This modification was implemented to enhance the peptide's structural stability and resistance to proteolytic degradation, making it more viable for persistent metabolic studies [3]. AOD-9604 typically utilizes a disulfide bridge between the cysteine residues at positions 7 and 14 to maintain its bioactive conformation.
Mechanism of Action: The Beta-3 AR Pathway
The primary mechanism of action for AOD-9604 involves the selective modulation of the beta-3 adrenergic receptor (β3-AR). These receptors are primarily located on the surface of adipocytes and are critical regulators of energy expenditure and thermogenesis [4].
When AOD-9604 engages the β3-AR signaling cascade, it initiates several intracellular events:
- Adenylate Cyclase Activation: Engagement of the receptor stimulates adenylate cyclase, converting ATP into cAMP.
- PKA Phosphorylation: Increased intracellular cAMP activates Protein Kinase A (PKA).
- HSL Activation: PKA phosphorylates Hormone-Sensitive Lipase (HSL), which hydrolyzes triglycerides into free fatty acids and glycerol [1].
- Lipogenesis Inhibition: AOD-9604 suppresses the activity of enzymes like acetyl-CoA carboxylase, essential for creating new fat stores [2].
Crucially, because AOD-9604 lacks the sequences necessary to bind the growth hormone receptor (GHR), it does not trigger the AKT/PI3K pathway. This metabolic selectivity is the hallmark of the fragment's research value.
Metabolic Evidence Comparison Table
| Research Subject | Observed Metabolic Outcome | Compound Tested | Maturity / Context |
|---|---|---|---|
| Obese (ob/ob) Mice | Significant increase in fat oxidation; reduction in adipose weight | AOD-9604 | Preclinical Standard [1] |
| Zucker (fa/fa) Rats | Reduction in body weight gain without affecting food intake | hGH 176-191 | Chronic Study [6] |
| Human Adipocytes (In Vitro) | Dose-dependent increase in lipolysis; inhibition of lipogenesis | AOD-9604 | Cellular Model [1] |
| Obese Human Volunteers | Modest weight loss (~2.6kg vs 0.8kg placebo); no IGF-1 rise | AOD-9604 | Phase IIb Clinical [10] |
| β3-AR Knockout Mice | Abolished lipolytic response to peptide stimulation | AOD-9604 | Mechanistic Proof [2] |
Primary Research Domains: Lipid Metabolism
The most robust domain of AOD-9604 literature centers on lipid metabolism and adipose tissue regulation. Early studies demonstrated that chronic administration in obese rodent models led to a significant reduction in visceral fat without any detectable change in total lean body mass or bone density [6].
In these models, the peptide appears to "prime" fat cells for metabolism by increasing the genetic expression of the beta-3 adrenergic receptor itself. Furthermore, AOD-9604 has been observed to enhance the metabolic rate in isolated tissue, suggesting a role in increasing thermogenesis [2,4]. Researchers often contrast this mechanism with that of 5-Amino-1MQ, which targets the NNMT enzyme rather than the adrenergic receptors.
Regenerative Potential: Cartilage and Joints
An emerging area of AOD-9604 research involves its potential role in joint health and cartilage regeneration. AOD-9604 appears to influence chondrocyte activity through independent pathways [4].
A landmark 2015 study utilizing a rabbit model of collagenase-induced osteoarthritis investigated the effects of intra-articular injections of AOD-9604. Researchers observed that the peptide, particularly when combined with hyaluronic acid, significantly improved cartilage regeneration and reduced histopathological damage scores compared to controls [4]. This regenerative focus makes it a candidate for studies alongside tissue-repair peptides like BPC-157 and TB-500.
Preclinical Limitations and Safety Profile
AOD-9604 clinical development as a weight-loss drug was discontinued after Phase IIb trials failed to demonstrate efficacy comparable to modern appetite suppressants or GLP-1 agonists [10].
From a safety perspective, AOD-9604 is remarkably stable and well-tolerated in laboratory settings. Human trials involving approximately 900 participants reported that the peptide did not induce neutralizing antibody formation and showed no adverse impact on insulin sensitivity or blood glucose levels [1,10]. However, since the compound is strictly for research use only, it has not been evaluated by regulatory bodies for consumer safety or therapeutic efficacy.
Related Metabolic Peptides
- HGH Fragment 176-191: The original, unmodified version lacking the N-terminal tyrosine.
- 5-Amino-1MQ: An NNMT inhibitor that increases intracellular NAD+ through a non-adrenergic pathway.
- BPC-157: Often studied alongside AOD-9604 in joint repair models.
- Ipamorelin: A growth hormone secretagogue that stimulates endogenous release of full-length hGH.
Where to Source AOD-9604 for Research
AOD-9604 is strictly classified as a research chemical and is not intended for human or veterinary use. Researchers must verify purity and identity through third-party analytical testing before inclusion in metabolic studies. When selecting a source, researchers should consult the guide to evaluating peptide suppliers.
- Short Chain Aminos — https://shortchainaminos.io
- BioPep — https://biopep.io/
- Catalyst Research — https://catalyst-research.net
- Apex Research Services — https://apexresearchservices.org
Frequently Asked Questions (FAQ)
How does AOD-9604 differ from full-length Growth Hormone (hGH)?
AOD-9604 is a small fragment of the 191-amino acid hGH protein modified to isolate the lipolytic domain, allowing fat-mobilization research without risks of insulin resistance or systemic anabolic signaling.
Is AOD-9604 associated with IGF-1 elevation in research?
No. Extensive preclinical and human clinical studies have confirmed that administration does not result in a significant increase in systemic IGF-1 levels.
How does AOD-9604 influence beta-3 adrenergic receptors?
AOD-9604 acts as a selective modulator of the β3-AR, stimulating the cAMP/PKA pathway to phosphorylate hormone-sensitive lipase, resulting in the breakdown of stored triglycerides.
Can AOD-9604 be used in joint repair research?
Yes. Preclinical studies have investigated AOD-9604 for cartilage regeneration in rabbit models of osteoarthritis, though human data remain limited.
Works Cited
- Heffernan M, et al. (2001). "The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism." J Endocrinol. PMID: 11713213.
- Ng FM, et al. (2000). "Metabolic Studies of a Synthetic Lipolytic Domain (AOD9604)." Horm Res. PMID: 11146367.
- Ng FM, et al. (2000). "The lipolytic and antilipogenic effects of HGH 177-191." Metabolism. PMID: 11673763.
- Lee MS, et al. (2015). "Intra-articular Injection of AOD9604 in Rabbit OA Model." J Orthop Res. PMID: 26275694.
- Cox HD, et al. (2015). "Detection of AOD9604 metabolites." Drug Test Anal. PMID: 25208511.
- Heffernan MA, et al. (2001). "hGH 177-191 increases fat oxidation in obese mice and Zucker rats." Am J Physiol. PMID: 11394015.
- Wu Z, Ng FM. (1993). "hGH 176-191 on lipolysis in obese rats." J Endocrinol. PMID: 8352664.
- Stier H, et al. (2013). "Safety and Tolerability of AOD9604 in Humans." J Endocrinol Metab.